Patents by Inventor Katsuo Hatayama

Katsuo Hatayama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5990151
    Abstract: The present invention relates to an optically active, substituted phenylalkylamine derivative represented by Formula [1]: ##STR1## wherein A is a substituted or non-substituted phenyl or thienyl; X.sup.1 is hydrogen, halogen, hydroxyl or a substituted or non-substituted C.sub.1-5 alkoxy; R.sup.1 and R.sup.2 are equally or differently hydrogen, C.sub.1-7 alkyl, C.sub.3-7 alkenyl or C.sub.3-7 alkynyl; R.sup.3 is C.sub.1-10 alkyl, C.sub.2-10 alkenyl or C.sub.2-10 alkynyl; n is an integer from 2 to 5; and m is an integer from 1 to 4,or a pharmaceutically acceptable salt thereof, and pharmaceutical use of such compound or salt. The compound of the invention is excellent in sigma 1 receptor antagonism and useful for treating schizophrenia, depression, anxiety, cerebrovascular diseases/senile troublesome behaviors, and cognitive dysfunctions and motor dysfunctions such as Alzheimer's disease, Parkinson's disease and Huntington's disease which are neurodegenerative diseases.
    Type: Grant
    Filed: May 15, 1998
    Date of Patent: November 23, 1999
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Atsuro Nakazato, Toshihito Kumagai, Tomoki Miyazawa, Koumei Ohta, Yutaka Kawashima, Katsuo Hatayama, deceased
  • Patent number: 5753673
    Abstract: Quinolinecarboxylic acid derivatives represented by the following formula: ##STR1## wherein C is hydroxymethyl, methoxy, ethoxy or morpholinyl, or pharmaceutically acceptable salts thereof exhibit a potent action for stimulating a serotonin 4 receptor. The compounds exhibit an action of enhancing the gastrointestinal motor function to improve the gastrointestinal conditions such as heartburn, anorexia, bowel pain, abdominal distension, etc., accompanied by chronic gastritis, diabetes mellitus or postoperative gastroparesis, and are thus effective for the treatment of gastro-esophagal reflux, intestinal pseudo-obstruction and constipation.
    Type: Grant
    Filed: January 18, 1996
    Date of Patent: May 19, 1998
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Yutaka Ohuchi, Masaji Suzuki, Hajime Asanuma, Sadakazu Yokomori, Katsuo Hatayama
  • Patent number: 5733917
    Abstract: Endo-(8-methyl-8-azabicyclo?3.2.1!oct-3-yl) 1-isopropyl-2(1H)-quinolone-3-carboxylate represented by Formula (I): ##STR1## or an acid addition salt thereof acts on a serotonin 4 receptor thereby to have a serotonin-like receptor stimulating activity, therefore has an action on activating gastrointestinal motor functions and thus is effective for the improvement of gastrointestinal conditions such as heartburn, anorexia, bowel pain or abdominal distension accompanied by chronic gastritis or postoperative gastroparesis, and further for the treatment of gastro-esophagal reflux, intestinal pseudo-obstruction or constipation.
    Type: Grant
    Filed: August 21, 1996
    Date of Patent: March 31, 1998
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Yutaka Ohuchi, Masaji Suzuki, Hajime Asanuma, Sadakazu Yokomori, Katsuo Hatayama, Yoshihiko Isobe, Haruko Kijima, Makoto Muramatsu
  • Patent number: 5712263
    Abstract: To provide novel steroid derivatives having an antitumor action which can be synthesized efficiently and stereoselectively by means of synthetic organic chemistry. A steroid derivative represented by the formula: ##STR1## wherein R is an alkyl group having 1 to 13 carbon atoms, A is a hydroxyl group or a group easily hydrolyzable to a hydroxyl group, X and Y together form an oxo group or an alkylenedioxy group having 2 or 3 carbon atoms, X is a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or a group easily hydrolyzable to a hydroxyl group, Y is a hydrogen atom or an alkoxy group having 1 to 5 carbon atoms, with the proviso that when X is a hydroxyl group or a group easily hydrolyzable to a hydroxyl group, Y is a hydrogen atom, and when X is an alkoxy group having 1 to 5 carbon atoms, Y is an alkoxy group having 1 to 5 carbon atoms, or a salt thereof.
    Type: Grant
    Filed: June 14, 1996
    Date of Patent: January 27, 1998
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Chihiro Yokoo, Hisaya Wada, Hidemichi Mitome, Tatsuhiko Sano, Katsuo Hatayama, Yasuji Yamada
  • Patent number: 5672712
    Abstract: Object: To provide compounds useful as inhibitors of blood platelet aggregation for intravenous administration.Constitution: A thiazoline derivative represented by the formula: ##STR1## ?wherein R.sup.1 is a hydroxyl group, an alkoxy group, a cycloalkoxy group or a group represented by the formula: R.sup.4 NH-- (wherein R.sup.4 is a cycloalkyl group), R.sup.2 is an alkyl group, a cycloalkyl group or a phenylalkyl group, R.sup.3 is a hydrogen atom or an alkyl group, and n is an integer of 2 to 9! or a salt thereof.
    Type: Grant
    Filed: December 12, 1996
    Date of Patent: September 30, 1997
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Masakazu Sato, Akira Manaka, Keiko Takahashi, Yutaka Kawashima, Katsuo Hatayama
  • Patent number: 5631354
    Abstract: Object:Provision of novel macrolide antibiotics having a strong antibacterial activity.Construction:Compounds represented by the formula: ##STR1## which are obtained by introducing a certain substituted carbonyloxy group into 5-O-desosaminylerythronolide derivatives at the 3-position; and pharmaceutically acceptable acid addition salts thereof.
    Type: Grant
    Filed: June 21, 1994
    Date of Patent: May 20, 1997
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Toshifumi Asaka, Yoko Misawa, Masato Kashimura, Shigeo Morimoto, Katsuo Hatayama
  • Patent number: 5631355
    Abstract: Object: To provide novel macrolide antibiotics having a strong antibacterial activity. Constitution: 5-O-desosaminylerythronolide A derivatives represented by the formula: ##STR1## [wherein -A- - is a group of --N(R.sup.3)-- (wherein R.sup.3 is a hydrogen atom or an alkyl group having 1-3 carbon atoms) or a group represented by --N.dbd., and R.sup.1 and R.sup.2 are each a hydrogen atom or an alkyl group having 1-3 carbon atoms] which is a tricyclic carbamate of 5-0-desosaminylerythronolide A derivative having a ketone at the 3-position, being substituted by a methoxy group at the 6-position, and a pharmaceutically acceptable acid addition salt thereof; and a compound represented by the formula: ##STR2## (wherein R.sup.4 is an acetyl group or a propionyl group) which is an intermediate useful for the preparation of the 3-ketone forms of 5-O-desosaminylerythronolide A derivatives.
    Type: Grant
    Filed: October 17, 1994
    Date of Patent: May 20, 1997
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Toshifumi Asaka, Masato Kashimura, Yoko Misawa, Shigeo Morimoto, Katsuo Hatayama
  • Patent number: 5602239
    Abstract: A novel macloride antibiotic having a potent antibacterial activity, represented by the formula: ##STR1## which is obtained by introducing a specific aryloxy or alkoxy group into the 3-position of a 5-O-desosaminylerythronolide derivative; or phamaceutically acceptable acid addition salts thereof.
    Type: Grant
    Filed: July 13, 1995
    Date of Patent: February 11, 1997
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Yoko Misawa, Toshifumi Asaka, Masato Kashimura, Shigeo Morimoto, Katsuo Hatayama
  • Patent number: 5597921
    Abstract: Indolo[2,3-b]quinoxaline derivatives represented by the following formula: ##STR1## wherein one of R.sup.1 and R.sup.2 is a hydrogen atom and the other is a group of the formula:--CH.sub.2 NHCCH.sub.3 (CH.sub.2 OH).sub.2,etc, and R.sup.3 is a hydrogen atom, a methyl group, etc.; and pharmaceutically acceptable salts thereof have an antitumor activity and are useful as medicines.
    Type: Grant
    Filed: October 16, 1995
    Date of Patent: January 28, 1997
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Taro Matsumoto, Hisaya Wada, Yoshihiro Migita, Katsuo Hatayama, Yoshinori Sekiguchi
  • Patent number: 5591837
    Abstract: Object: To provide a novel macrolide antibiotic having a strong antibacterial activity.Constitution: 11-Amino-3,11-dideoxy-3-oxo-5-O-desosaminyl-6-O-methylerythronolide A 11-N,12-O-cyclic carbamate which has a ketone at the 3-position and a methylated hydroxyl group at the 6-position of a 5-O-desosaminylerythronolide A derivative, and pharmaceutically acceptable acid addition salts thereof.
    Type: Grant
    Filed: October 14, 1994
    Date of Patent: January 7, 1997
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Toshifumi Asaka, Masato Kashimura, Yoko Misawa, Shigeo Morimoto, Katsuo Hatayama
  • Patent number: 5571820
    Abstract: Endo-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1 -isopropyl-2(1H)-quinolone-3-carboxamide shown by formula (I): ##STR1## or an acid addition salt thereof exhibits a potent action for stimulating a serotonin 4 receptor and is effective for the treatment of diseases and for the improvement of conditions, caused by a reduced motility in the gastrointestinal tract.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: November 5, 1996
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Yutaka Ohuchi, Masaji Suzuki, Hajime Asanuma, Sadakazu Yokomori, Katsuo Hatayama, Yoshihiko Isobe, Chika Ito, Makoto Muramatsu
  • Patent number: 5523399
    Abstract: Provision of novel macrolide antibiotics having a strong antibacterial activity.Construction:Compounds represented by the formula: ##STR1## which are obtained by introducing a carbamoyl group into 5-O-desosaminyl-6-O-methylerythronolide derivatives at the 3-position; and pharmaceutically acceptable acid addition salts thereof.
    Type: Grant
    Filed: June 20, 1994
    Date of Patent: June 4, 1996
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Toshifumi Asaka, Yoko Misawa, Masato Kashimura, Shigeo Morimoto, Katsuo Hatayama
  • Patent number: 5521311
    Abstract: The present compounds represented by the formula: ##STR1## (wherein R.sup.1 is a phenyl group, a halophenyl group or a cycloalkyl group having 3 to 8 carbon atoms, R.sup.2 is a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, R.sup.3 is a hydrogen atom, an alkyl group having 1 to 7 carbon atoms, a cycloalkyl group having 3 to 8 carbon atoms, an alkenyl group having 3 to 5 carbon atoms or a benzyl group, or R.sup.2 and R.sup.3 are bonded together to form a 5- to 7-membered heterocycle) and salts thereof have potent anti-inflammatory, antipyretic, analgesic and anti-allergic actions with less side effects such as gastrointestinal disorders and with such a high safety as to permit long-term administration.
    Type: Grant
    Filed: August 14, 1995
    Date of Patent: May 28, 1996
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Kensei Yoshikawa, Shiuji Saito, Yohichi Shimazaki, Mariko Kashiwa, Katsuo Hatayama
  • Patent number: 5502202
    Abstract: Object: To provide an antipsychotic drug being different in functional mechanism from dopamine autoreceptor agonists, namely, to provide an antipsychotic drug having a specific affinity for a sigma receptor and causing no extrapyramidal disorder.Constitution: An aminoalkylthiazole derivative represented by formula: ##STR1## (wherein R.sup.1 represents a phenyl group substituted with a halogen atom; R.sup.2 and R.sup.3 are either the same or different and each represents an alkyl group having 4 to 10 carbon atoms; and n is 2 or 3;) and a salt thereof.
    Type: Grant
    Filed: November 29, 1993
    Date of Patent: March 26, 1996
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Atsuro Nakazato, Yoshinori Sekiguchi, Yutaka Kawashima, Katsuo Hatayama
  • Patent number: 5496829
    Abstract: 2-nitroxyethyl (+)apovincaminate is used as an agent for relieving disturbance of consciousness and as a narcotic antagonist.
    Type: Grant
    Filed: May 24, 1994
    Date of Patent: March 5, 1996
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Shigeru Okuyama, Susumu Otomo, Yutaka Kawashima, Katsuo Hatayama
  • Patent number: 5495046
    Abstract: An alkoxyphenylalkylamine derivative represented by the following formula: ##STR1## (wherein X.sup.1 and X.sup.2 may be either the same or different from each other and each represents a hydrogen atom, a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkoxy group having 1 to 5 carbon atoms and substituted with a phenyl group; R.sup.1 and R.sup.2 may be either the same or different from each other and each represents a hydrogen atom, an alkyl group having 1 to 7 carbon atoms, an alkyl group having 1 to 7 carbon atoms and substituted with "a hydroxyl group, a carboxyl group or an alkoxycarbonyl group" at the end, or, R.sup.1 and R.sup.
    Type: Grant
    Filed: March 31, 1994
    Date of Patent: February 27, 1996
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Atsuro Nakazato, Yoshinori Sekiguchi, Koumei Ohta, Yutaka Kawashima, Katsuo Hatayama
  • Patent number: 5478945
    Abstract: A thiazoline derivative represented by the formula: ##STR1## [wherein R.sup.1 is cyano, carbamoyl, thiocarbamoyl, morpholinothiocarbonyl, alkylthioimidoyl, amidino, substituted amidino or imidazolin-2-yl, R.sup.2 is alkyl or aralkyl, R.sup.3 is hydrogen or alkyl, R.sup.4 is hydroxyl, alkoxy, substituted alkoxy or amino, l is an integer of 1 to 5] and salts thereof have fibrinogen receptor antagonism and cell adhesion factor antagonism, and are useful as therapeutic agents for ischemic diseases and atherosclerosis diseases, and metastasis inhibitory agents of tumors.
    Type: Grant
    Filed: January 11, 1995
    Date of Patent: December 26, 1995
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Masakazu Sato, Akira Manaka, Keiko Takahashi, Yutaka Kawashima, Katsuo Hatayama
  • Patent number: 5475130
    Abstract: An anilide derivative useful as an atherosclerosis treating drug, represented by the following formula (I): ##STR1## wherein X is an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms; Y is a hydrogen atom or an alkoxy group having 1 to 4 carbon atoms; Z is an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms; A is an alkylene group having 1 to 4 carbon atoms; R is an alkyl group having 6 to 20 carbon atoms, an alkanoyl group having 2 to 20 carbon atoms or a benzyl group which may be substituted with an alkyl group having 1 to 4 carbon atoms; and n is 0, 1 or 2.
    Type: Grant
    Filed: May 25, 1993
    Date of Patent: December 12, 1995
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Masakazu Sato, Yutaka Kawashima, Katsuo Hatayama
  • Patent number: 5449826
    Abstract: To provide an excellent compound having anti-inflammatory, antipyretic, analgesic and antirheumatic actions.A 5-amino-2-phenoxysulfonanilide compound represented by the formula: ##STR1## and the salts thereof have potent anti-inflammatory, antipyretic, analgesic and antirheumatic actions, and therefore they are useful as anti-inflammatory, antipyretic, analgesic and antirheumatic agents.
    Type: Grant
    Filed: December 9, 1994
    Date of Patent: September 12, 1995
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Kensei Yoshikawa, Shuji Saito, Yohichi Shimazaki, Mariko Kashiwa, Katsuo Hatayama
  • Patent number: 5416212
    Abstract: An anilide compound represented by formula (I): ##STR1## wherein R.sup.1 and R.sup.2, which may be the same or different, each represent an alkyl group having 1 to 4 carbon atoms; n represents 0, 1 or 2; A represents an alkylene group having 1 to 14 carbon atoms or a group represented by --CH.sub.2 CO--; and Ar represents a phenyl group, a phenyl group substituted with a halogen atom, a nitro group, an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, an alkanoyl group having 2 to 5 carbon atoms or a trifluoromethyl group, a benzyl group, a pyridyl group, a pyridyl group substituted with a halogen atom or a trifluoromethyl group, or a pyrimidyl group, or a salt thereof. The disclosed anilide compounds have potent ACAT inhibitory activity.
    Type: Grant
    Filed: June 20, 1994
    Date of Patent: May 16, 1995
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Masakazu Sato, Masahiro Kawase, Akira Manaka, Yutaka Kawashima, Katsuo Hatayama